布地奈德福莫特罗吸入剂对支气管哮喘缓解期炎症因子干预效果  

Effect of Budesonide Formoterol inhalation on inflammatory factors of bronchial asthma in remission stage

作　　者：陈亚飞[1] 张瑞[1] 

机构地区：[1]新乡市中心医院,河南新乡453000

出　　处：《包头医学院学报》2018年第1期63-64,共2页Journal of Baotou Medical College

摘　　要：目的:探讨布地奈德福莫特罗吸入剂对支气管哮喘缓解期炎症因子干预效果。方法:180例支气管哮喘患者随机分为观察组与对照组,对照组患者给予口服孟鲁司特咀嚼片,观察组在此基础上给予布地奈德福莫特罗吸入剂治疗,对比两组患者的临床治疗效果。结果:观察组患者治疗后FEV1、FVC、FEV1/FVC均优于对照组治疗后(P<0.05),IL-4、TNF-α、IL-5也优于对照组(P<0.05);观察组患者的整体治疗满意度(90.0%)高于对照组(80.0%)(P<0.05)。结论:布地奈德福莫特罗吸入剂能够改善患者的IL-4、TNF-α、IL-5,还能够改善患者的肺功能并提高患者的治疗满意度。Objective：To investigate the effect of Budesonide Formoterol inhalation on inflammatory factors of bronchial asthma in remission stage.Methods：180 cases of bronchial asthma patients were randomly divided into observation group and control group.The control group was treated with oral montelukast chewable tablets,and the observation group was additionally given Budesonide Formoterol inhalation.The clinical treatment effect in the two groups was compared.Results：FEV1,FVC and FEV1/FVC after treatment in the observation group were better than those in the control group（P〈0.05）,and IL-4,TNF-α and IL-5 were better than those in the control group（P〈0.05）.The overall treatment satisfaction of the observation group（90.00 %） was higher than that in the control group（80.00 %）（P〈0.05）.Conclusion：Budesonide Formoterol inhalation can improve IL-4,TNF-α and IL-5 in the patients with bronchial asthma.Furthermore,it can improve the patient＇s lung function and their satisfaction with treatment.

关 键 词：布地奈德福莫特罗吸入剂 支气管哮喘 炎症因子 

分 类 号：R562.25[医药卫生—呼吸系统]